Integra LifeSciences (NASDAQ:IART) Sees Large Volume Increase

Integra LifeSciences Holdings Co. (NASDAQ:IART) saw strong trading volume on Tuesday . 439,018 shares changed hands during mid-day trading, a decline of 43% from the previous session’s volume of 765,387 shares.The stock last traded at $23.29 and had previously closed at $23.14.

Analysts Set New Price Targets

IART has been the topic of several analyst reports. Bank of America cut their price target on shares of Integra LifeSciences from $42.00 to $26.00 and set an “underperform” rating on the stock in a report on Tuesday. StockNews.com lowered Integra LifeSciences from a “buy” rating to a “hold” rating in a research note on Tuesday, April 30th. Morgan Stanley cut their price objective on Integra LifeSciences from $37.00 to $24.00 and set an “underweight” rating on the stock in a research report on Tuesday. Citigroup upgraded Integra LifeSciences from a “sell” rating to a “neutral” rating and set a $38.00 target price for the company in a research report on Wednesday, April 3rd. Finally, Wells Fargo & Company cut shares of Integra LifeSciences from an “overweight” rating to an “equal weight” rating and cut their price target for the stock from $45.00 to $25.00 in a report on Tuesday. Three equities research analysts have rated the stock with a sell rating, six have issued a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat, Integra LifeSciences has an average rating of “Hold” and an average price target of $36.80.

Integra LifeSciences Price Performance

The stock has a 50 day moving average price of $32.44 and a two-hundred day moving average price of $38.06. The firm has a market cap of $1.99 billion, a PE ratio of 30.48, a price-to-earnings-growth ratio of 0.87 and a beta of 1.17. The company has a quick ratio of 2.18, a current ratio of 3.45 and a debt-to-equity ratio of 0.94.

Integra LifeSciences (NASDAQ:IART) last issued its earnings results on Monday, May 6th. The life sciences company reported $0.55 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.55. The company had revenue of $368.90 million during the quarter, compared to analyst estimates of $361.96 million. Integra LifeSciences had a return on equity of 15.19% and a net margin of 4.39%. The firm’s quarterly revenue was down 3.2% on a year-over-year basis. During the same quarter last year, the business posted $0.74 EPS. As a group, equities analysts expect that Integra LifeSciences Holdings Co. will post 3.19 earnings per share for the current year.

Institutional Trading of Integra LifeSciences

Hedge funds have recently modified their holdings of the stock. State Board of Administration of Florida Retirement System increased its holdings in Integra LifeSciences by 18.6% in the first quarter. State Board of Administration of Florida Retirement System now owns 81,614 shares of the life sciences company’s stock valued at $2,893,000 after buying an additional 12,777 shares in the last quarter. Russell Investments Group Ltd. boosted its position in Integra LifeSciences by 8.0% during the first quarter. Russell Investments Group Ltd. now owns 50,502 shares of the life sciences company’s stock worth $1,790,000 after purchasing an additional 3,743 shares in the last quarter. Headlands Technologies LLC increased its position in shares of Integra LifeSciences by 54.3% in the first quarter. Headlands Technologies LLC now owns 4,764 shares of the life sciences company’s stock valued at $169,000 after buying an additional 1,677 shares in the last quarter. Inspire Investing LLC raised its stake in shares of Integra LifeSciences by 14.8% during the 1st quarter. Inspire Investing LLC now owns 10,143 shares of the life sciences company’s stock worth $360,000 after buying an additional 1,311 shares during the period. Finally, Concurrent Investment Advisors LLC lifted its position in shares of Integra LifeSciences by 17.3% during the 1st quarter. Concurrent Investment Advisors LLC now owns 16,943 shares of the life sciences company’s stock valued at $601,000 after buying an additional 2,500 shares in the last quarter. Hedge funds and other institutional investors own 84.78% of the company’s stock.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.